Download Centre

Download the Brochure

---

Videos

• Drug Discovery and the Market Today
  Dr. David Elder is the Externalization Director for GlaxoSmithKline. Here, he talks exclusively on his perspective across the industry, including CROs, regulations, and strategising for efficiency, all ahead of his participation in this year's Improving Solubility conference.
• Part 1: An overview of externalisation in the Pharma industry
• Part 2: Critical thoughts on stability
• Part 3: The focus on solubility
• Part 4: Developing amorphous forms
• Part 5: Considering genotoxic and carcinogenic impurities

---

Webinars

---

Podcast

• Liposomes, nanotechnology and the industry today
  Professor Yvonne Perrie, Chair in Drug Delivery at the School of Life and Health Sciences at Aston University, joins us to discuss the latest advancements in the field of solubility and the recent activity of the UKICRS.

---

Articles

• Nanotechnology puts drug solubility under the microscope
  
  In the world of drug development, the effectiveness of a product to handle or treat medical conditions is only one concern for companies. An issue of equal importance is how the items react while inside the body, including whether they are formulated in a suitable manner which makes them soluble enough.
  
  >>read more
• Seeking bioequivalence in solubility
  
  Like many aspects of the pharmaceutical industry, solubility is a complex area which covers a range of techniques and strategies integral to drug development. Scientists face the responsibility of running their products through a range of assessments in order to gauge their suitability for the consumer market.
  
  >>read more
• Does the future of solubility lie in HME
  
  When it comes to drug development, pharmaceutical firms face a number of difficult challenges as they aim to create new, safe products to combat a range of illnesses. However, on occasion, all of their hard work can be in vain, particularly when products fail to react in the correct manner when tested.
  
  >>read more
• Nanotechnologies Solving the Insoluble
  
  According to studies, nanotechnologies can lead to improved targeting to organsand extended release of a drug. They offer pioneering strategies to solve many of the problems latent in drug development, including solubility.
• Predicting Aqueous Solubility From Structure
  
  John S.Delaney, DRUG DISCOVERY TODAY: BIOSILICO
  The aqueous solubility of a drug is one of the key physical properties that affect both its ADME profile and ‘screenability’ in HTS. This review critically surveys a range of methods that can be used to predict the solubility of a compound in water and presents some of the main issues that affect the applicability of different techniques. As ever, there are trade-offs to be made between the speed, accuracy and transparency of methods, but current programs can provide estimates to well within an order of magnitude in favourable cases. The need for new ways to predict solubility in more challenging systems (e.g. solvents such as DMSO and charged solutes) is discussed.
• Solubility: It’s Not Just For Physical Chemists
  
  Shobha N. Bhattachar, Laura A. Deschenes and James A. Wesley Drug Discovery Today
  Solubility data are used to make crucial decisions from the earliest stages of drug discovery throughout the development process, but often the decision-maker is far removed, in terms of both organization and scientific background, from the scientist who generates the data. Here we provide a reference point for consumers of solubility who are presented with increasingly sophisticated strategies to measure sooner, faster or more accurately. We discuss the fundamental forces that govern solubility, the role of physical–chemical parameters such as pH and pKa, and the principles involved in different solubility measurements. Our ultimate goal is to enable a decision-maker, when presented with solubility data, to have in hand the tools to evaluate not just the magnitude but also the context and appropriateness of those measurements to the drug in question.
• Biological Assay Challenges From Compound Solubility: Strategies For Bioassay Optimization
  
  Li Di and Edward H. Kerns Drug Discovery Today
  Compound solubility in buffers and dimethyl sulfoxide (DMSO) has emerged as an important issue. Many discovery compounds have low solubility but are potentially valuable as leads. Unfortunately, low solubility affects bioassays by causing underestimated activity, reduced HTS-hit rates, variable data, inaccurate SAR, discrepancies between enzyme and cell assays and inaccurate in vitro ADME–Tox testing. Strategies for optimizing bioassays include: considering solubility in HTS-library design; early screening for solubility; improving storage and handling of DMSO stocks; optimizing dilution protocols; and ensuring that low-solubility compounds are fully solubilized in bioassays. These approaches allow for adequate assessments of aluable pharmacophores for which solubility can be chemically optimized at a later date.

---

Top Presentations of Improving Solubility 2009

• Approaches and Considerations in Selecting Formulations for Toxicity Studies Involving Low Solubility Compounds
  By:
  Dr Gary Eichenbaum and Dr Albertina Arien, Johnson & Jonhson
• Case Study: Amorphous Techniques in Poorly Soluble Drug Candidates
  By:
  Marco Gil, Hovione
• Building Experimental and Predictive Technologies into a Strategy for Progressing Poorly Soluble Drugs to the Patient
  By :
  Dr Matthew Ling

---

Content Library

[ Register Now ]